Reference entry · Short-acting GHRH analog
CJC-1295 (no DAC)
Also known as: Mod GRF(1-29) · CJC-1295 without DAC
- Class
- Short-acting GHRH analog
- Primary targets (literature)
- GHRH receptor
- Regulatory context
- Not FDA-approved. Not interchangeable with CJC-1295 (with DAC) without explicit identity proof.
Overview
The no-DAC form of CJC-1295 is a shorter-acting GHRH analog than the DAC-modified variant. Research discussions often pair it with ipamorelin or GHRP-class peptides — combination data remain predominantly preclinical.
Mechanism in research literature
GHRH receptor agonism at the pituitary with shorter exposure than DAC-modified analogs, producing pulsatile GH-axis research profiles in published models.
Common research focus areas
- Pulsatile GH release research designs
- PK comparison vs. DAC form
- Combination protocol literature (preclinical)
- Mod GRF(1-29) sequence verification
Full literature roundup
Read the cited research summary
The shorter-acting tetrasubstituted GHRH(1-29) analog. How it differs from the DAC form, what literature reports, and COA expectations.
CJC-1295 (no DAC) research roundup · 5 minEvaluate catalog material
- COA literacy — read batch documentation before comparing vendors.
- Peptide identity testing — why sequence confirmation matters beyond purity %.
- How we vet sources — our score methodology for recommended vendors.